Compare ESQ & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESQ | ARCT |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.0M | 245.4M |
| IPO Year | 2017 | 2019 |
| Metric | ESQ | ARCT |
|---|---|---|
| Price | $105.02 | $7.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $120.33 | $24.11 |
| AVG Volume (30 Days) | 91.6K | ★ 369.6K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | 14.20 | ★ 20.00 |
| EPS | ★ 1.40 | N/A |
| Revenue | N/A | ★ $82,031,000.00 |
| Revenue This Year | $35.15 | N/A |
| Revenue Next Year | $39.09 | $12.77 |
| P/E Ratio | $75.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $87.54 | $5.85 |
| 52 Week High | $119.86 | $24.14 |
| Indicator | ESQ | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 45.08 | 37.93 |
| Support Level | $104.58 | $6.90 |
| Resistance Level | $111.41 | $7.88 |
| Average True Range (ATR) | 2.47 | 0.65 |
| MACD | -0.28 | -0.17 |
| Stochastic Oscillator | 24.78 | 3.44 |
Esquire Financial Holdings Inc is a financial holding company operating as a full service commercial bank. It serves the financial needs of the litigation industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The bank offers tailored financial and payment processing solutions to the litigation community and their clients as well as dynamic and flexible payment processing solutions to small business owners. It operates in one operating segment, that of community banking.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.